Daxxify
Daxxify (daxxibotulinumtoxinA-lanm) is a novel neuromodulator approved by the FDA in 2022 for the temporary improvement of frown lines (glabellar lines) in adults. Like Botox, Dysport, Xeomin, and Jeuveau, it’s a botulinum toxin type A product, but Daxxify sets itself apart with some notable differences in formulation, duration, and delivery method.
Daxxify Services
1. Longer Duration of Effect
Key differentiator: Daxxify can last up to 6 months or longer for many patients, while most other neuromodulators typically last about 3 to 4 months. (delete space)Clinical trials have shown some patients maintained results for up to 9 months, depending on individual metabolism and dosage.
2. Peptide Technology (No Human or Animal-Based Proteins)
- Daxxify uses a unique peptide-stabilized formulation called Peptide Exchange Technology
, which helps extend its duration.
3. Reduced Treatment Frequency
- With results potentially lasting 2x as long, many patients may require only two treatments per year, compared to 3–4 with traditional products—appealing for those seeking low-maintenance aesthetics.
- Longer-lasting results mean fewer appointments and potentially lower annual costs despite a possibly higher upfront price.
- Ideal for people who:
- Have busy schedules or travel frequently.
- Desire a more sustained aesthetic result.
- Are resistant to other neuromodulators or experience shorter-than-average duration with Botox, etc.
Daxxify has a similar safety profile to other neuromodulators. Common side effects include headache, injection site pain, eyelid drooping, and facial asymmetry. Rare but serious effects may involve allergic reactions or muscle weakness spreading beyond the injection area. Because it lasts longer, unwanted effects may persist longer than with Botox or similar products. It’s not recommended for those who are pregnant, breastfeeding, or have neuromuscular disorders.